P2Y12 Inhibitor-Based Monotherapy

被引：0
|
作者：
Choudhary, Rahul [1 ]
Deora, Surender [1 ]
机构：
[1] All India Inst Med Sci, Dept Cardiol, Jodhpur 342005, Rajasthan, India
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2020年 / 76卷 / 10期
关键词：
TICAGRELOR; ASPIRIN;
D O I：
10.1016/j.jacc.2020.06.075
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1273 / 1274
页数：2
相关论文
共 50 条
  • [41] CLINICAL OUTCOMES OF P2Y12 INHIBITOR MONOTHERAPY IN PATIENTS UNDERGOING TRANSCATHETER AORTIC VALVE REPLACEMENT: LESS IS MORE!
    Ibrahim, Homam
    Staniloae, Cesar
    Fuentes, Jorge
    Gonzalez-Lengua, Carlos
    Vidal, Samantha
    Gaudio, Stephanie
    Tovar, Joseph
    Jilaihawi, Hasan
    Querijero, Michael
    Neuburger, Peter
    Williams, Mathew
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (18) : 1173 - 1173
  • [42] Reversible P2Y12 inhibitor versus irreversible P2Y12 inhibitor in ACS patients undergoing PCI (the acute coronary syndrome israeli survey (ACSIS)
    Eliaz, R.
    Mengesha, B.
    Ovdat, T.
    Iakobishvili, Z.
    Hasdai, D.
    Kheifets, M.
    Klempfner, R.
    Beigel, R.
    Kalmanovich, E.
    Alcalai, R.
    Levi, A.
    EUROPEAN HEART JOURNAL, 2021, 42 : 1414 - 1414
  • [43] P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy After Deployment of a Drug-Eluting Stent
    Min, Pil-Ki
    Kang, Tae Soo
    Cho, Yun-Hyeong
    Cheong, Sang-Sig
    Kim, Byeong-Keuk
    Kwon, Sung Woo
    Park, Woo Jung
    Lee, Jung-Hee
    Kim, Wonho
    Lee, Wang-Soo
    Yoon, Young Won
    Lee, Byoung Kwon
    Kwon, Hyuck Moon
    Hong, Bum-Kee
    JAMA NETWORK OPEN, 2024, 7 (03) : E240877
  • [44] Outcomes with P2Y12 inhibitor monotherapy after PCI according to bleeding risk: A Bayesian meta-analysis
    Woelders, Eva C. I.
    Luijkx, Jasper J. P.
    Rodwell, Laura
    Winkler, Patty J. C.
    Dimitriu-Leen, Aukelien C.
    Smits, Pieter C.
    van Royen, Niels
    Hof, Arnoud W. J. van't
    Damman, Peter
    Geuns, Robert Jan M. van
    CARDIOVASCULAR REVASCULARIZATION MEDICINE, 2023, 55 : 44 - 51
  • [45] P2Y12 Inhibitor Monotherapy: Considerations for Acute and Long-Term Secondary Prevention Post-PCI
    Greco, Antonio
    Mauro, Maria Sara
    Capodanno, Davide
    Angiolillo, Dominick J.
    REVIEWS IN CARDIOVASCULAR MEDICINE, 2022, 23 (10)
  • [46] P2Y12 Inhibitor Monotherapy After Short-Term Dual Antiplatelet Therapy in Acute Coronary Syndrome
    Singh, Sahib
    Garg, Aakash
    Tantry, Udaya S.
    Bliden, Kevin
    Abbott, J. Dawn
    Gurbel, Paul A.
    AMERICAN JOURNAL OF CARDIOLOGY, 2024, 224 : 1 - 8
  • [47] Aspirin-free P2Y12 inhibitor monotherapy immediately after percutaneous coronary intervention: A systematic review
    Yu, Shenglong
    Guo, Linjuan
    Guo, Huizhuang
    HELIYON, 2024, 10 (15)
  • [48] Personalized P2Y12 Inhibitor Treatment Are We Ready to Go?
    ten Berg, Jurrien M.
    Janssen, Paul W. A.
    JACC-CARDIOVASCULAR INTERVENTIONS, 2020, 13 (05) : 631 - 633
  • [49] Efficient synthesis of prasugrel, a novel P2Y12 receptor inhibitor
    Pan, Xianhua
    Huang, Rui
    Zhang, Jianshui
    Ding, Liping
    Li, Weijin
    Zhang, Qunhui
    Liu, Feng
    TETRAHEDRON LETTERS, 2012, 53 (40) : 5364 - 5366
  • [50] Is P2Y12 inhibitor therapy associated with an increased risk of cancer?
    Kaufmann, Christoph C.
    Lyon, Alexander R.
    Wojta, Johann
    Huber, Kurt
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2019, 5 (02) : 100 - 104
12345